Vanda Pharmaceuticals | VNDA - Selling And Administration Expenses

Stock Price
7.44
Daily Change
0.02 0.27%
Monthly
0.40%
Yearly
56.63%
Q1 Forecast
4.24

Vanda Pharmaceuticals reported $39.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Anika Therapeutics USD 12.91M 17.8M Mar/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Insmed USD 186.38M 109.94M Sep/2025
J&J USD 6.75B 831M Dec/2025
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 268M 38M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Veracyte USD 51.73M 5.91M Sep/2025